GPCR Quote, Financials, Valuation and Earnings

Amgen has a net margin of -- compared to Structure Therapeutics's net margin of 6.9%. Structure Therapeutics's return on equity of -- beat Amgen's return on equity of 66.87%.

Structure Therapeutics has a consensus price target of $80.15, signalling upside risk potential of 237.63%. On the other hand Amgen has an analysts' consensus of $314.62 which suggests that it could grow by 12.03%. Given that Structure Therapeutics has higher upside potential than Amgen, analysts believe Structure Therapeutics is more attractive than Amgen.

Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amgen has a beta of 0.583, suggesting its less volatile than the S&P 500 by 41.682%.

Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.25% to investors and pays a quarterly dividend of $2.38 per share. Structure Therapeutics pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

Structure Therapeutics quarterly revenues are --, which are smaller than Amgen quarterly revenues of $9.1B. Structure Therapeutics's net income of -$36.5M is lower than Amgen's net income of $627M. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Amgen's PE ratio is 37.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus 4.54x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -- compared to Structure Therapeutics's net margin of 32.59%. Structure Therapeutics's return on equity of -- beat Eli Lilly and's return on equity of 80.24%.

Structure Therapeutics has a consensus price target of $80.15, signalling upside risk potential of 237.63%. On the other hand Eli Lilly and has an analysts' consensus of $1,008.64 which suggests that it could grow by 14.03%. Given that Structure Therapeutics has higher upside potential than Eli Lilly and, analysts believe Structure Therapeutics is more attractive than Eli Lilly and.

Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.61% to investors and pays a quarterly dividend of $1.50 per share. Structure Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Structure Therapeutics quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Structure Therapeutics's net income of -$36.5M is lower than Eli Lilly and's net income of $4.4B. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 75.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus 17.75x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Terns Pharmaceuticals has a net margin of -- compared to Structure Therapeutics's net margin of --. Structure Therapeutics's return on equity of -- beat Terns Pharmaceuticals's return on equity of --.

Structure Therapeutics has a consensus price target of $80.15, signalling upside risk potential of 237.63%. On the other hand Terns Pharmaceuticals has an analysts' consensus of $19.06 which suggests that it could grow by 552.83%. Given that Terns Pharmaceuticals has higher upside potential than Structure Therapeutics, analysts believe Terns Pharmaceuticals is more attractive than Structure Therapeutics.

Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Terns Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Structure Therapeutics pays -- of its earnings as a dividend. Terns Pharmaceuticals pays out -- of its earnings as a dividend.

Structure Therapeutics quarterly revenues are --, which are smaller than Terns Pharmaceuticals quarterly revenues of --. Structure Therapeutics's net income of -$36.5M is lower than Terns Pharmaceuticals's net income of -$21.8M. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Terns Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus -- for Terns Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -- compared to Structure Therapeutics's net margin of --. Structure Therapeutics's return on equity of -- beat Viking Therapeutics's return on equity of --.

Structure Therapeutics has a consensus price target of $80.15, signalling upside risk potential of 237.63%. On the other hand Viking Therapeutics has an analysts' consensus of $89.50 which suggests that it could grow by 258.14%. Given that Viking Therapeutics has higher upside potential than Structure Therapeutics, analysts believe Viking Therapeutics is more attractive than Structure Therapeutics.

Structure Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.838, suggesting its less volatile than the S&P 500 by 16.205%.

Structure Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Structure Therapeutics pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Structure Therapeutics quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Structure Therapeutics's net income of -$36.5M is higher than Viking Therapeutics's net income of -$45.6M. Notably, Structure Therapeutics's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics is -- versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.